Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baclofen + oxybutynin is a combination of two small molecule drugs used primarily in the management of overactive bladder (OAB) with abnormal voiding patterns. Baclofen is a gamma-aminobutyric acid (GABA) agonist that acts as a skeletal muscle relaxant, reducing spasticity by activating GABA-B receptors in the central nervous system[6]. Oxybutynin is an antimuscarinic agent that works by relaxing the muscles in the bladder, thereby reducing symptoms such as urgency, frequency, and urge incontinence[4][7]. The combination has been studied for its ability to reduce voiding difficulty associated with antimuscarinic therapy in women with OAB and abnormal voiding patterns; adding baclofen to oxybutynin may help mitigate these difficulties[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on baclofen + oxybutynin.